Literature DB >> 29602572

Non-specific gastrointestinal features: Could it be Fabry disease?

Max J Hilz1, Eloisa Arbustini2, Lorenzo Dagna3, Antonio Gasbarrini4, Cyril Goizet5, Didier Lacombe5, Rocco Liguori6, Raffaele Manna7, Juan Politei8, Marco Spada9, Alessandro Burlina10.   

Abstract

Non-specific gastrointestinal symptoms, including pain, diarrhoea, nausea, and vomiting, can be the first symptoms of Fabry disease. They may suggest more common disorders, e.g. irritable bowel syndrome or inflammatory bowel disease. The confounding clinical presentation and rarity of Fabry disease often cause long diagnostic delays and multiple misdiagnoses. Therefore, specialists involved in the clinical evaluation of non-specific upper and lower gastrointestinal symptoms should recognize Fabry disease as a possible cause of the symptoms, and should consider Fabry disease as a possible differential diagnosis. When symptoms or family history suggest Fabry disease, in men, low alpha-galactosidase A enzyme levels, and in women, specific Fabry mutations confirm the diagnosis. In addition to symptomatic treatments, disease-specific enzyme replacement therapy with recombinant human alpha-galactosidase A enzyme or chaperone therapy (migalastat) in patients with amenable mutations can improve the disease, including gastrointestinal symptoms, and should be initiated as early as possible after Fabry disease has been confirmed; starting enzyme replacement therapy at as young an age as possible after diagnosis improves long-term clinical outcomes. Improved diagnostic tools, such as a modified gastrointestinal symptom rating scale, may facilitate diagnosing Fabry disease in patients with gastrointestinal symptoms of unknown cause and thus assure timely initiation of disease-specific treatment.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Abdominal pain; Diarrhoea; Enzyme replacement therapy; Fabry disease; Lysosomal storage disorders; OMIM #301500; Rare diseases

Mesh:

Substances:

Year:  2018        PMID: 29602572     DOI: 10.1016/j.dld.2018.02.011

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  10 in total

Review 1.  Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review.

Authors:  Claudia Regenbogen; Matthias Christoph Braunisch; Christoph Schmaderer; Uwe Heemann
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.

Authors:  Robert J Hopkin; Ulla Feldt-Rasmussen; Dominique P Germain; Ana Jovanovic; Ana Maria Martins; Kathleen Nicholls; Alberto Ortiz; Juan Politei; Elvira Ponce; Carmen Varas; Frank Weidemann; Meng Yang; William R Wilcox
Journal:  Mol Genet Metab Rep       Date:  2020-10-30

Review 3.  Fabry Disease: The Current Treatment Landscape.

Authors:  Malte Lenders; Eva Brand
Journal:  Drugs       Date:  2021-03-15       Impact factor: 9.546

4.  Pathologic substrate of gastropathy in Anderson-Fabry disease.

Authors:  Alessandro Di Toro; Nupoor Narula; Lorenzo Giuliani; Monica Concardi; Alexandra Smirnova; Valentina Favalli; Mario Urtis; Costanza Alvisi; Elena Antoniazzi; Eloisa Arbustini
Journal:  Orphanet J Rare Dis       Date:  2020-06-22       Impact factor: 4.123

Review 5.  Storage diseases with hypertrophic cardiomyopathy phenotype.

Authors:  Luis Ruiz-Guerrero; Roberto Barriales-Villa
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

Review 6.  Fabry disease - a multisystemic disease with gastrointestinal manifestations.

Authors:  Malte Lenders; Eva Brand
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 7.  Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I.

Authors:  Chiara Rossi; Gloria Simoncelli; Giovanni Arpa; Alessandra Stracuzzi; Paola Parente; Matteo Fassan; Alessandro Vanoli; Vincenzo Villanacci
Journal:  Pathologica       Date:  2021-12-02

8.  The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.

Authors:  Ana M Martins; Gustavo Cabrera; Fernando Molt; Fernando Suárez-Obando; Régulo A Valdés; Carmen Varas; Meng Yang; Juan M Politei
Journal:  JIMD Rep       Date:  2019-08-05

Review 9.  Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.

Authors:  Fabio Caputo; Lisa Lungaro; Adriana Galdi; Eleonora Zoli; Fiorella Giancola; Giacomo Caio; Roberto De Giorgio; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2021-03-23       Impact factor: 3.390

10.  FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.

Authors:  Alan L Shields; Roger E Lamoureux; Fiona Taylor; Jay A Barth; Andrew E Mulberg; Vivian Kessler; Nina Skuban
Journal:  Qual Life Res       Date:  2021-04-29       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.